

Biological Research For Nursing

Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children with Leukemia

Journal:	<i>Biological Research for Nursing</i>
Manuscript ID	BRN-ROR-19-01-0010.R1
Manuscript Type:	Report of Original Research
Keywords:	childhood leukemia, symptom trajectory, oxidative stress biomarker, inflammatory biomarker, longitudinal parallel process

SCHOLARONE™
Manuscripts

Abstract

Purpose: The purpose of this study was to explore the influence of oxidative stress (F2-isoprostanes) and inflammatory (IL-8) biomarkers on symptom trajectories during the first 18 months of childhood leukemia treatment.

Method: A repeated-measures design was used to evaluate symptom experienced by 218 children during treatment. A symptom cluster (fatigue, pain, and nausea) was explored over four time periods: initiation of post-induction therapy, 4 and 8 months post-induction therapy, and the beginning of maintenance therapy (12 months post induction). F2-isoprostanes and IL-8 were evaluated in cerebrospinal fluid (CSF) samples collected at the baseline (diagnosis) and then at the subsequent four time periods. The longitudinal relationships of these biomarkers with the symptom cluster were examined using the longitudinal parallel process.

Results: Pain and fatigue levels were highest during the post-induction phases of treatment, and then decreased slightly during maintenance therapy; while nausea scores were relatively stable. Even in the later phases of treatment, children continued to experience symptoms. CSF levels of the biomarkers increased during the post-induction phases of treatment. Early increases in the biomarkers were associated with more severe symptom during the same period; patients who had increased biomarkers over time also experienced more severe symptoms over time.

Conclusions: Findings reveal that children experience symptoms throughout the course of leukemia treatment, and support hypothesized longitudinal relationships of oxidative stress and inflammatory biomarkers with symptom severity. Activation of the biomarker pathways during treatment may explain underlying mechanisms of symptom experiences and identify which children are at risk for severe symptoms.

Keywords: childhood leukemia; symptom trajectory; oxidative stress biomarker; inflammatory biomarker; longitudinal parallel process

Introduction

Childhood leukemia treatment over the last three decades has resulted in survival rates that exceed 80% (Hunger et al., 2012; Tasian et al., 2015). Intensity of treatment required for cure has created numerous side-effects that often are overlooked. Fatigue, pain, nausea, depression, sleep disturbances, mental exhaustion and changes in activity are the most common treatment-related symptoms that can profoundly impact children's lives. Up to 80% of children with cancer experience at least one symptom during treatment but on average children experience more than 10 symptoms during therapy (Baggott et al., 2012; Yeh et al., 2008). Treatment-related pain, nausea, and fatigue (Hedstrom et al., 2003) were the most common symptoms in a group of 121 children with cancer. Physical symptoms were common (prevalence > 35%) in a group of 160 children with cancer and included lack of energy, pain, drowsiness, nausea, cough, and lack of appetite (Collins et al., 2000). Parents of cancer patients and health care professionals reported by proxy that cancer-related fatigue was a frequent symptom experienced during treatment (Gibson et al., 2005). In a study of health-related quality of life (HRQOL) in 61 children following myelosuppressive chemotherapy, those with poorer functional status and higher symptom burden were associated with significant decreases in HRQOL; children experienced on average, 10.6 separate symptoms. The most common symptoms included lack of energy, pain, feeling drowsy, nausea, and feeling sad and irritable (Baggott et al., 2010). In a recent published study by this research team, children with leukemia 3 to 18 years old experienced sleep disturbance and nausea that had limited change over time. Fatigue, pain, and depression decreased over four time periods; however, none of the symptoms completely resolved over time (Hockenberry et al., 2017).

The majority of childhood cancer symptom research has been among heterogeneous groupings of pediatric oncology diagnoses (Hinds et al., 2007), which limits ability to tailor interventions for children, as specific diagnoses and treatment modalities are likely associated with

1
2
3 differing symptom profiles. There is limited understanding of the underlying mechanisms
4 associated with symptom severity and why significant variations occur even when disease and
5 treatment are similar. Based on our prior work, we focused on the selected~~The potential~~
6 ~~influence of~~ inflammatory and oxidative stress responses during the most intensive phase of
7 childhood leukemia treatment that may influence symptom toxicities and should be explored
8 (Caron et al., 2009; Hockenberry et al., 2014, 2015; Moore et al., 2015, 2018; Rodgers et al.,
9 2016; Stenzel et al., 2010).

10
11
12
13
14
15
16
17
18 The inflammatory pathways ~~are is~~ designed to clear an organism of the cause of cell
19 injury (e.g. microorganisms, toxins) and the consequences of injury (e.g. necrotic cells, tissues).
20 Inflammation is controlled by a host of extracellular mediators and regulators, including
21 cytokines which act as key modulators of inflammation (Turner et al., 2014). IL-8 (CXCL8) is a
22 critical inflammatory mediator and is elevated in many chronic inflammatory conditions found in
23 adults; important examples include psoriasis, adult respiratory syndrome, chronic obstructive
24 pulmonary disease, diabetes, chronic liver disease, polyarthritis, and asthma. Investigators
25 report that in various cancers upregulation of IL-8 is often correlated with disease activity
26 (Donnelly et al., 1993; Koch et al., 1991; Nakamura et al., 1992; Qiao et al., 2016; Zimmermann
27 et al., 2011). Increased inflammatory biomarkers have also been observed in children with
28 numerous illnesses such as juvenile idiopathic arthritis (Sznurkowska et al., 2018), acute kidney
29 injury (Greenberg et al., 2018), and children who are maltreated (Coelho et al., 2014). IL-8
30 shows recent promise as a biomarker for acute child and adolescent psychopathology (Gariup
31 et al., 2015).

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Oxidative stress refers to cellular injury and degeneration caused by reactive oxygen
species (ROS). ROS are reactive because they act as an electron acceptor and “steal”
electrons from other molecules. These compounds damage cell structures, especially lipids.
Compared to other organs, the brain is particularly vulnerable to oxidative stress due to limited
antioxidant capacity, greater energy requirements, and higher lipid content (Floyd, 1999).

1
2
3 Methotrexate, a drug given by multiple routes (intravenous, oral, and intrathecal) and commonly
4 used for acute lymphoblastic leukemia (ALL) treatment, decreases antioxidant defense resulting
5 in increased oxidative stress, and methotrexate-induced oxidative stress has been observed in
6 the brain (Hockenberry et al., 2014). ROS have been linked to the pathophysiology of numerous
7 disorders including traumatic brain injury, ischemia-reperfusion injury, atherosclerosis,
8 inflammatory diseases, cancer, adriamycin-induced cardiomyopathy, neuro-degenerative
9 conditions, and age-related functional decline (Hannun, 1996; Liou et al., 2003; Margaiil et al.,
10 2005; Minuz et al., 2006; Montine et al., 2005; Pellegrini-Giampietro et al., 1990; Pratico et al.,
11 1998; Pyne-Geithman et al., 2005; Shohami et al., 1997; Weber, 1994). Two published studies
12 evaluated an oxidative stress measure, total antioxidant capacity (TAC), in children with cancer.
13 TAC was evaluated in 20 children with cancer at the time of diagnosis and during the first three
14 cycles of chemotherapy and revealed significant decreases in TAC over time, suggesting an
15 oxidative stress additive effect that could impact response to treatment, disease course, and
16 prognosis (Papageorgiou et al., 2005). In another study of 13 children with leukemia and various
17 solid tumors, TAC was impaired in both groups; however, higher oxidative stress occurred in the
18 leukemia group (Mazor et al., 2008).

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The purpose of this study was to explore the influence of inflammatory and oxidative stress biomarkers on specific symptom trajectories during the first 18 months of childhood leukemia treatment. Inflammatory and oxidative stress biomarkers were measured in cerebrospinal fluid (CSF) samples during diagnostic and therapeutic lumbar punctures at baseline. We hypothesized that increased levels of inflammatory and oxidative stress biomarkers would be associated with more severe symptom experiences during ALL treatment.

Conceptual Model

The conceptual framework for this study (Figure 1) proposed that the physiologic responses to leukemia treatment involve activation of inflammatory and oxidative stress pathways (measured by CSF biomarkers), which will influence the number and severity of

1
2
3 symptoms during childhood cancer therapy. Chemotherapy agents commonly used for
4 childhood leukemia (e.g., methotrexate) can increase reactive oxygen species (ROS) production
5 as a result of altered folate metabolism and decreased antioxidant enzyme production. These
6 chemotherapy agents also are associated with an inflammatory response that induces cytokine
7 release. A key factor underlying the organizational framework for this study is that individual
8 phenotypic susceptibility to oxidative stress release and inflammatory response can contribute
9 to subsequent clinical outcomes and symptom severity.
10
11
12
13
14
15
16
17
18
19

20 **Methods**

21 **Design**

22 A repeated-measures longitudinal design was used to evaluate treatment-related
23 symptom associations experienced by 218 children and adolescents 3 to 18 years of age
24 receiving ALL treatment. Symptom trajectories were explored over four time periods: initiation of
25 post-induction therapy, 4 and 8 months during post-induction therapy, and the beginning of
26 maintenance/continuation therapy (12 months post induction). Symptom measures included
27 fatigue, pain, and nausea. Oxidative stress (F2-isoprostanes) and inflammatory (IL-8)
28 biomarkers were measured in cerebrospinal fluid (CSF) samples obtained at diagnosis
29 (baseline) and at four time points during ALL treatment (Times 1 through 4).
30
31
32
33
34
35
36
37
38
39
40

41 **Settings and Sample**

42 The settings for this study were four major childhood cancer treatment centers in the
43 United States. When combined, the four centers diagnose more than 200 children and
44 adolescents with leukemia who meet the study eligibility criteria each year. Children with a
45 cognitive disability identified pre-leukemia diagnosis were ineligible for study enrollment.
46
47
48
49
50

51 The sample size for this study was 218. All the participants provided complete
52 information about sociodemographic variables (age, sex, race/ethnicity) and leukemia risk
53 category. Leukemia risk category is determined by specific factors (biological and genetic
54
55
56
57
58
59
60

1
2
3 features of the leukemia cells, age, gender, and initial response to therapy) known to predict
4 survival or relapse. There were intermittent, longitudinal missing data (3.7% to 28.4%) across all
5
6 the time points among the longitudinal variables. Fortunately, Little's (1988) missing completely
7
8 at random (MCAR) test showed that the missing data were MCAR ($\chi^2(1236) = 1223.82, p =$
9
10 .592) and did not have a negative impact on parameter estimation (Little & Rubin, 2002). Thus,
11
12 an expectation–maximization (EM) algorithm was performed for missing data imputation on the
13
14 two baseline biomarker measures. Baseline biomarker measurements, sociodemographic
15
16 variables, and leukemia risk category were controlled for as covariates in the main analysis. As
17
18 for the longitudinal missing data on the biomarkers and the symptom measures from Time 1 to
19
20 Time 4, they were automatically handled in multilevel modeling within the two-step longitudinal
21
22 parallel-process technique described below.
23
24
25

26 **Leukemia Treatment**

27
28 Children were treated on an ALL protocol. Induction therapy (1 month) included weekly
29
30 treatment with vincristine and daunomycin (for high-risk ALL), a corticosteroid and a dose of
31
32 Peg-asparaginase, and two intrathecal methotrexate (IT MTX) treatments (Days 1 and 29).
33
34 Post-induction therapy (6–8 months) involved several courses of treatment that included
35
36 asparaginase, high- or intermediate-dose intravenous (IV) MTX (depending on ALL protocol
37
38 assignment), vincristine, doxorubicin, corticosteroid, cytarabine, and mercaptopurine. During
39
40 post-induction IT MTX was given on Day 1 of each 12-week cycle. Throughout therapy, study
41
42 participants received CNS prophylaxis with standardized doses of IT MTX based on
43
44 age. Maintenance/continuation therapy with the final study measurement, began 6 to 8 months
45
46 after the end of induction therapy. Time intervals for each phase of treatment were influenced
47
48 by participants' side effects and recovery from low blood counts.
49
50

51 **Data Collection**

52
53
54 Consent was obtained from a parent or legal guardian. Children (age seven years of age
55
56 and older) and adolescents provided assent. Symptom assessments were obtained using
57
58
59
60

1
2
3 standardized instruments and occurred during a routine follow-up clinic visit; time points were
4
5 chosen to evaluate the most intensive phase of therapy post-induction. CSF samples were
6
7 collected in conjunction with the lumbar puncture for IT MTX treatment that coincided most
8
9 closely with symptom data collection.
10

11 **Measures**

12
13 Symptom Measures and Cluster. Based on our previous findings (Hockenberry et al.,
14
15 2017) we focused on the 3-three symptoms of fatigue, pain, and nausea. Symptoms were
16
17 assessed using valid and reliable measures; data on each symptom was collected with a table
18
19 PC (iPad). This study used a technological n innovative approach to symptom assessment by
20
21 measuring each symptom using a separate reliable and validated instrument (see Table 1) with
22
23 a tablet PC (iPad). English and Spanish versions of the instruments were available on the tablet
24
25 PC. Standardized measures evaluated fatigue, pain, and nausea. For consistency across
26
27 symptoms, parent proxy was used for the 3-6-year-old age group and symptom self-report for
28
29 children ≥ 7 years of age. Specifically, fatigue was measured by three instruments according
30
31 to used for the different age ranges: the Child Fatigue Scale (CFS; Hinds et al., 2010) for ages 7-
32
33 12, the Adolescent Fatigue Scale (FSA; Mandrell et al., 2011) for ages 13-18, and the Parent
34
35 Fatigue Scale (PFS; Hockenberry et al., 2003) fro ages 3-6. Then, all the scores from the three
36
37 instruments were converted to comparable, standardized T-scores. All symptoms were reported
38
39 over the past 2-4 weeks. Data collection required less than 25 minutes to complete at each time
40
41 point. For each symptom scale, a higher score indicates greater symptom severity. Scores were
42
43 used to determine symptom severity and classified into different symptom profiles labeled as
44
45 mild, moderate and severe (see Table 1).
46
47
48

49 Because the three symptom measures (fatigue, pain, and nausea) were highly
50
51 correlated with each other at each time point (Hockenberry et al., 2017), they were combined as
52
53 a symptom cluster- through exploratory factor analysis with maximum likelihood estimation
54
55
56
57
58
59
60

1
2
3 which returned a one-factor solution with significant factor loadings from .35 to .88 and at least
4
5 54% of variance explained at each time point (Table 14).
6

7 **CSF cytokine measures.** Two milliliters of CSF were obtained in conjunction with
8 diagnostic and therapeutic lumbar punctures as part of clinical treatment. CSF samples were
9 placed on ice and processed within 2 hours of collection to prevent reactions such as auto-
10 oxidation. Samples were centrifuged at 4°C to remove any particulates, aliquoted and frozen at -
11 80°C, and shipped on dry ice to the core research lab for this study. IL-8 was measured using a
12 cytokine-specific, AlphaLISA immunoassay kit (Perkin-Elmer) as instructed by the manufacturer.
13 This is a luminescent, homogenous (no wash) proximity-based assay with extremely high
14 sensitivity and a wide (4 logs) dynamic range. Each sample was assayed in triplicate wells of
15 96-well, half-area white plates. Briefly, each well contained 10 µL of blank (artificial CSF with
16 Prionex), sample, or standard and 20 µL of Acceptor Bead Solution. Once the Acceptor Bead
17 Solution was added to the plate, it was sealed and incubated at room temperature for 1-hour.
18 After 1-hour and under low light, 20 µL of Donor Bead Solution was added to each well and
19 incubated at room temperature for 30-minutes. The plate seal was removed under low light and
20 plates were read at 615 nm wavelength using a Perkin-Elmer Envision multilabel plate reader
21 equipped with the Alpha option. Cytokine concentrations were determined by comparison to a
22 standard curve of recombinant cytokine, using a linear regression logistic equation, and
23 expressed as pg/ml.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **CSF oxidative stress measures.** CSF samples for the oxidative stress biomarker were
44 obtained at the same time as the cytokine samples, processed, and stored as described above.
45 F₂-isoprostanes (F₂-IsoPs) are a sensitive non-invasive index of oxidative stress *in vivo*, and
46 were measured by a competitive enzyme-linked immunoassay (ELISA) kit according to
47 instructions (Cayman Chemical). The kit was designed for extraction-free analysis of bodily
48 fluids including CSF and has been validated for detection of 8-F₂-IsoP in urine, plasma and
49 other sample matrices. Briefly, each well contained 50 µl of sample or standard, 50 µl of 8-F₂-
50
51
52
53
54
55
56
57
58
59
60

1
2
3 IsoP AChE Tracer, and 50 μ l of 8-F₂-IsoP Antiserum. Plates were incubated for 18 hours at 4°C.
4
5 Wells were then washed 5 times with 200 μ l of wash buffer at room temperature. Ellman's
6
7 Reagent (200 μ l) was added to each well. A Total Activity well contained only Ellman's Reagent
8
9 and Tracer added just before the second incubation. A Reaction Blank contained only Ellman's
10
11 Reagent, and a Non-Specific Binding well contained only Tracer, added before incubation, and
12
13 Ellman's Reagent. Plates were covered and placed on an orbital shaker at 400rpm for 90 to 120
14
15 min at room temperature. The plate was then read on a Perkin Elmer Envision Multi-label Plate
16
17 Reader at 405nm. Average replicates of each standard (0.08 pg/ml to 500 pg/ml) were used to
18
19 generate the standard curve. CSF samples were analyzed in triplicate to confirm reproducibility
20
21

22 **Statistical Analyses**

23
24 Descriptive statistics were computed for sample characteristics (sociodemographics and
25
26 leukemia risk category) and the baseline biomarker information (Table 2) as well as the
27
28 longitudinal variables measured from Time 1 to Time 4 (Table 3).
29

30
31 To test the hypothesis that participants who had increased F₂-isoprostanes and IL-8
32
33 biomarkers during the post-induction phase of treatment would experience higher severity of
34
35 symptoms, longitudinal relationships were examined from the initiation of post-induction therapy
36
37 (Time 1) to 4 and 8 months post-induction therapies (Times 2 & 3) to the beginning of
38
39 maintenance/continuation therapy (Time 4), controlling for sociodemographics, leukemia risk
40
41 category, and the baseline biomarkers. The longitudinal nature was expressed by the growth
42
43 parameters—the initial status (or intercept) and the rate of change (or slope)—of the longitudinal
44
45 variables.
46

47
48 More specifically, the longitudinal parallel process (LPP; Cheong et al., 2003), a process
49
50 of two-step modeling, was utilized to test hypothesized longitudinal relationships. In the first
51
52 step, the intercept and slope of each of the longitudinal variables were estimated separately by
53
54 using univariate growth models with multilevel modeling in SAS Proc Mixed (SAS Institute,
55
56 2011). Such separate modeling helps not only manage the unbalanced, intermittent longitudinal
57
58
59
60

1
2
3 missing data across the different longitudinal variables, but also easily control for covariates,
4 such as the sociodemographic and other baseline variables, in the estimation of the intercepts
5 and slopes of the longitudinal variables so that the covariates would not need to be controlled
6 again in the second step. Due to its modeling flexibility, LPP is increasingly reported in the
7 literature for studies with longitudinal measurements (Dowling et al., 2015; Petrou et al., 2018;
8 Sousa et al., 2014; Winkler et al., 2017; Yiotaldiotariotam et al., 2013).

9
10
11 In the second step, structural equation modeling was employed for testing the
12 longitudinal relationships between the biomarkers and symptom cluster using IBM SPSS Amos
13 (Arbuckle, 2010). The structural equation model fit was evaluated using the following model-fit
14 indices: chi-square of the estimated model (χ^2), goodness of fit index (GFI), normed fit index
15 (NFI), incremental fit index (IFI), relative fit index (RFI), comparative fit index (CFI), and root
16 mean square error of approximation (RMSEA). A nonsignificant chi-square value ($p > .05$)
17 suggests a good overall model fit to the data. For GFI, NFI, IFI, RFI, and CFI, values larger than
18 .90 indicate that the model provides a good fit to the data, whereas RMSEA should be below
19 .06. The fit indices and their criteria are commonly recommended in the literature (Hu and
20 Bentler, 1999; Kline, 2005).

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Results**

Descriptive Statistics

Table 2 shows that among 218 participants in the study sample, the average age was 8.38 years ($SD = 4.48$). Sex was unbalanced with more boys than girls (56.0% vs. 44.0%); and race/ethnicity was even more unbalanced with nearly half being Hispanic (43.6%), 39.9% being non-Hispanic white, and much fewer being non-Hispanic black and non-Hispanic others (both 8.3%). As for leukemia risk category, 32.6% of the participants in the study sample were at very high risk, 21.6% at high risk, 34.9% at average or standard risk, and 11.0% at low risk. The

means of the two biomarkers at baseline were 8.38 (pg/ml) ($SD = 10.42$) for F2-isoprostanes and 142.77 (pg/ml) ($SD = 112.20$) for IL-8.

The means and standard deviations of the longitudinal variables across the four time points (Table 3) demonstrate that fatigue and pain decreased over time; whereas nausea remained almost the same from Time 1 to Time 3 before it decreased from Time 3 to Time 4. Both biomarkers greatly decreased from Time 1 to Time 2 and then remained almost the same for the remaining time points.

~~Because the three symptom measures (fatigue, pain, and nausea) were highly correlated with each other at each time point (Hockenberry et al., 2017), they were combined as a symptom cluster through exploratory factor analysis with maximum likelihood estimation which returned a one factor solution with significant factor loadings from .35 to .88 and at least 54% of variance explained at each time point (Table 4).~~

Longitudinal Relationships

The model-fit indices for the initially hypothesized longitudinal relationships were satisfactory ($\chi^2(6) = 6.12$, $p = .409$; GFI = .99, NFI = .99, IFI = 1.00, RFI = .97, CFI = 1.00; and RMSEA = .010), but one path coefficient (i.e., from the intercept of F2-isoprostanes to the slope of symptom cluster) was not significant at the $\alpha = .10$ level. To obtain a parsimonious model, the non-significant path coefficient was removed in the final model. Thus, a final parsimonious model was reached as shown in Figure 2 with the standardized estimates of path coefficients. The model fit indices for the parsimonious model improved and all remained satisfactory ($\chi^2(7) = 6.13$, $p = .525$; GFI = .99, NFI = .99, IFI = 1.00, RFI = .97, CFI = 1.00; and RMSEA < .001).

From Figure 2, we can conclude that the positive, longitudinal relationships between biomarkers and symptom cluster did exist in the data. Specifically, patients with an initial high level of both biomarkers also experienced higher severity of symptoms initially ($\beta = .24$, $p < .001$ for F2-isoprostanes and $\beta = .21$, $p < .001$ for IL-8). For patients who had increased biomarkers

1
2
3 during the post-induction phase of treatment, they also experienced higher severity of
4 symptoms over time ($\beta = .14, p = .035$ for F2-isoprostanes and $\beta = .30, p = .015$ for IL-8). In
5 addition, for patients with an initial high level of IL-8, they experienced marginally higher severity
6 of symptoms over time ($\beta = .22, p = .082$).
7
8
9
10
11
12
13

14 Discussion

15
16 Pain and fatigue levels were highest during the post-induction phase of treatment (Times
17 1 and 2), and then decreased slightly during maintenance therapy. This finding confirms that
18 during the first few months of leukemia therapy, children experience the most intense
19 symptoms. However, even at the later phase of treatment, children continued to experience
20 symptoms. Nausea scores were in the mild range and relatively stable at all 4 measurement
21 times consistent with the type of chemotherapy being administered for leukemia.
22
23
24
25
26
27
28

29 Increased levels of IL-8 and F2-isoprostanes in CSF samples were found, which
30 suggests that inflammatory and oxidative stress pathways are activated in response to ALL
31 treatment. As hypothesized, we also found that higher levels of these CSF biomarkers were
32 associated with more severe symptoms. This study continues to support the influence of
33 pediatric leukemia chemotherapy drugs on ROS production as by-products of cellular toxicity.
34 Evidence supports that the oxidative stress pathway is interactive and may result in significant
35 cellular toxicity. The current study's findings add to the evidence that activation of the oxidative
36 stress pathway can induce numerous somatic symptoms; two previous studies specifically
37 evaluating biomarkers for oxidative stress also confirmed activation of the oxidative stress
38 pathway during childhood cancer treatment (Mazor et al., 2008; Papageorgiou et al., 2005).
39
40
41
42
43
44
45
46
47
48
49

50 These collective findings suggest that early increases in inflammatory and oxidative
51 stress may be useful in identifying which children are at greater risk of experiencing treatment-
52 related symptoms and in developing novel interventions to mitigate symptom severity. As
53
54
55
56
57
58
59
60

1
2
3 oxidative stress biological markers continue to be identified and described, it may be possible to
4 determine individual susceptibility to oxidative stress and its influence on clinical outcomes and
5 symptom severity in the future. As childhood cancer treatment continues to advance and more
6 children are cured of their disease, findings from this work have the potential to allow
7 individualized treatment focused on curing disease. Nursing interventions to minimize symptom
8 toxicities can then be focused on the specific trajectories unique to each child with cancer.

9
10
11 It is worth noting that the study finding was based on only two biomarkers and three
12 symptom measures. More biomarkers and more symptom measures would be interesting to be
13 examined in future research for obtaining more robust results. In addition, the study finding was
14 also based on a convenience sample from only four specific health systems. A larger
15 randomized-cluster multi-site study on the topic in future research would be also desirable to
16 provide more comprehensive evidence for informing future nursing research and practice.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Declaration of Conflicting Interests

The Authors declare that there is no conflict of interest.

For Peer Review

References

- 1
2
3
4
5 Arbuckle, J. L. (2010). *IBM SPSS Amos 19 user's guide*. Crawfordville, FL: Amos Development
6 Corporation.
7
8
9 Baggott, C., Cooper, B. A., Marina, N., Matthay, K. K., & Miaskowski, C. (2012). Symptom
10 cluster analyses based on symptom occurrence and severity ratings among pediatric
11 oncology patients during myelosuppressive chemotherapy. *Cancer Nursing*, *35*, 19-28.
12
13
14 Baggott, C., Dodd, M., Kennedy, C., Marina, N., Matthay, K. K., Cooper, B. A., & Miaskowski, C.
15 (2010). Changes in children's reports of symptom occurrence and severity during a
16 course of myelosuppressive chemotherapy. *Journal of Pediatric Oncology Nursing*, *27*,
17 307-315.
18
19
20 Caron, J. E., Krull, K. R., Hockenberry, M., Jain, N., Kaemingk, K. & Moore, I. M. (2009).
21 Oxidative stress and executive function in children receiving chemotherapy for acute
22 lymphoblastic leukemia. *Pediatric Blood & Cancer*, *53*(4), 551-556.
23
24
25
26
27
28
29
30 Cheong, J., Mackinnon, D. P., Khoo, S. T. (2003). Investigation of mediational processes using
31 parallel process latent growth curve modeling. *Structural Equation Modeling*, *10*, 238.
32
33
34 Coelho, R., Viola, T. W., Walss-Bass, C., Brietzke, E., & Grassi-Oliveira, R. (2014). Childhood
35 maltreatment and inflammatory markers: a systematic review. *Acta Psychiatrica*
36 *Scandinavica*, *129*, 180-192.
37
38
39
40
41 Collins, J. J., Byrnes, M. E., Dunkel, I. J., Lapin, J., Nadel, T., Thaler, H. T., ... Portenoy, R. K.
42 (2000). The measurement of symptoms in children with cancer. *Journal of Pain and*
43 *Symptom Management*, *19*, 363-377.
44
45
46
47
48 Donnelly, S. C., Strieter, R. M., Kunkel, S. L., Walz, A., Robertson, C. R., Carter, D. C., ...
49 Haslett, C. (1993). Interleukin-8 and development of adult respiratory distress syndrome
50 in at-risk patient groups. *Lancet*, *341*, 643-647.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Dowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. J. (2015). The mediational effects
4 of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and
5 neurocognitive function. *Neuroimage*, *105*, 357-368.
6
7
8
9
10 Floyd, R. A. (1999). Antioxidants, oxidative stress, and degenerative neurological disorders.
11 *Proceedings of the Society for Experimental Biology and Medicine*, *222*, 236-245.
12
13
14 Gariup, M., Gonzalez, A., Lazaro, L., Torres, F., Serra-Pages, C., & Morer, A. (2015). IL-8 and
15 the innate immunity as biomarkers in acute child and adolescent psychopathology.
16 *Psychoneuroendocrinology*, *62*, 233-242.
17
18
19
20 Gibson, F., Garnett, M., Richardson, A., Edwards, J., & Sepion, B. (2005). Heavy to carry: a
21 survey of parents' and healthcare professionals' perceptions of cancer-related fatigue in
22 children and young people. *Cancer Nursing*, *28*, 27-35.
23
24
25
26 Greenberg, J. H., Zappitelli, M., Jia, Y., Thiessen-Philbrook, H. R., de Fontnouvelle, C. A.,
27 Wilson, F. P., Coca, S., Devarajan, P., & Parikh, C. R. (2018). Biomarkers of AKI
28 progression after pediatric cardiac surgery. *Journal of the American Society of*
29 *Nephrology*, *29*, 1549-1556.
30
31
32
33
34
35 Hannun, Y. A. (1996). Functions of ceramide in coordinating cellular responses to stress.
36 *Science*, *274*, 1855-1859.
37
38
39 Hedstrom, M., Haglund, K., Skolin, I., & von Essen, L. (2003). Distressing events for children
40 and adolescents with cancer: child, parent, and nurse perceptions. *Journal of Pediatric*
41 *Oncology Nursing*, *20*, 120-132.
42
43
44
45 Hinds, P.S., Hockenberry, M., Tong, X., Rai, S.N., Gattuso, J. S., McCarthy, K., ... Srivastava,
46 D. K. (2007). Validity and reliability of a new instrument to measure cancer-related
47 fatigue in adolescents. *Journal of Pain and Symptom Management*, *34*, 607-618.
48
49
50
51 Hinds, P. S., Yang, J., Gattuso, J. S., Hockenberry, M., Jones, H., Zupanec, S., ... Srivastava D.
52 K. (2010). Psychometric and clinical assessment of the 10-item reduced version of the
53
54
55
56
57
58
59
60

1
2
3 Fatigue Scale-Child instrument. *Journal of Pain and Symptom Management*, 39, 572-
4
5 578.
6

7 Hockenberry, M. J., Hinds, P. S., Barrera, P., Bryant, R., Adams-McNeill, J., Hooke, C., ...
8
9 Manteuffel, B. (2003). Three instruments to assess fatigue in children with cancer: the
10
11 child, parent and staff perspectives. *Journal of Pain and Symptom Management*, 25,
12
13 319-328.
14

15
16 Hockenberry, M. J., Hooke, M. C., Rodgers, C., Taylor, O., Koerner, K. M., Mitby, P., ... Pan, W.
17
18 (2017). Symptom trajectories in children receiving treatment for leukemia: a latent class
19
20 growth analysis with multitrajectory modeling. *Journal of Pain and Symptom*
21
22 *Management*, 54, 1-8.
23

24 [Hockenberry, M. J., Krull, K. R., Insel, K. C., Harris, L. L., Gundy, P. M., Adkins, K. B., ... Moore,](#)
25
26 [I. M. \(2015\). oxidative stress, motor abilities, and behavioral adjustment in children](#)
27
28 [treated for acute lymphoblastic leukemia. *Oncology Nursing Forum*, 42\(5\), 542-549.](#)
29

30
31 Hockenberry, M. J., Taylor, O. A., Gundy, P. M., Ross, A. K., Pasvogel, A., Montgomery, D., ...
32
33 Moore, I. (2014). F2-isoprostanes: a measure of oxidative stress in children receiving
34
35 treatment for leukemia. *Biological Research for Nursing*, 16, 303-309.
36

37 Hu, L. T., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis:
38
39 Conventional criteria versus new alternatives. *Structural Equation Modeling*, 6, 1-55.
40

41 Hunger, S. P., Lu, X., Devidas, M., Camitta, B. M., Gaynon, P. S., Winick, N. J., ... Carroll, W. L.
42
43 (2012). Improved survival for children and adolescents with acute lymphoblastic
44
45 leukemia between 1990 and 2005: a report from the children's oncology group. *Journal*
46
47 *of Clinical Oncology*, 30, 1663-1669.
48

49 Kline, R. B. (2005). *Principles and practice of structural equation modeling* (2nd ed.) New York,
50
51 NY: The Guilford Press.
52
53
54
55
56
57
58
59
60

- 1
2
3 Koch, A. E., Kunkel, S. L., Burrows, J. C., Evanoff, H. L., Haines, G. K., Pope, R. M., & Strieter,
4
5 R. M. (1991). Synovial tissue macrophage as a source of the chemotactic cytokine IL-8.
6
7 *Journal of Immunology*, 147, 2187-2195.
8
- 9 Liou, A. K., Clark, R. S., Henshall, D. C., Yin, X. M., & Chen, J. (2003). To die or not to die for
10
11 neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated
12
13 signaling pathways and apoptotic pathways. *Progress in Neurobiology*, 69, 103-142.
14
- 15 Little, R. J. A. (1988). A test of missing completely at random for multivariate data with missing
16
17 values. *Journal of the American Statistical Association*, 83, 1198-1202.
18
- 19 Little, R. J. A., & Rubin, D. B. (2002). *Statistical analysis with missing data*. New York, NY:
20
21 Wiley.
22
- 23 Mandrell, B. N., Yang, J., Hooke, M. C., Wang, C., Gattuso, J. S., Hockenberry, M., ...Hinds,
24
25 P.S. (2011). Psychometric and clinical assessment of the 13-item reduced version of the
26
27 fatigue scale-adolescent instrument. *Journal of Pediatric Oncology Nursing*, 28, 287-294.
28
- 29 Margaille, I., Plotkine, M., & Lerouet, D. (2005). Antioxidant strategies in the treatment of stroke.
30
31 *Free Radical Biology and Medicine*, 39, 429-443.
32
- 33 Mazor, D., Abucoider, A., Meyerstein, N., & Kapelushnik, J. (2008). Antioxidant status in
34
35 pediatric acute lymphocytic leukemia (ALL) and solid tumors: The impact of oxidative
36
37 stress. *Pediatric Blood & Cancer*, 51(5), 613-615.
38
- 39 Minuz, P., Fava, C., & Cominacini, L. (2006). Oxidative stress, antioxidants, and vascular
40
41 damage. *British Journal of Clinical Pharmacology*, 61, 774-777.
42
- 43 Montine, T. J., Montine, K. S., McMahan, W., Markesbery, W. R., Quinn, J. F., & Morrow, J. D.
44
45 (2005). F2-isoprostanes in Alzheimer and other neurodegenerative diseases.
46
47 *Antioxidants and Redox Signaling*, 7, 269-275.
48
- 49
50
51 Moore, I. M., Gundy, P., Pasvogel, A., Montgomery, D. W., Taylor, O. A., Koerner, K., ...
52
53 Hockenberry, M. J. (2015). Increase in oxidative stress as measured by cerebrospinal
54
55

fluid lipid peroxidation during treatment for childhood acute lymphoblastic leukemia.

Journal of Pediatric Hematology and Oncology, 37(2), e86-e93.

Moore, I. M., Koerner, K. M., Gundy, P. M., Montgomery, D. W., Insel, K. C., Harris, L. L., ...

Hockenberry, M. J. (2018). Changes in oxidant defense, apoptosis, and cognitive

abilities during treatment for childhood leukemia. *Biological Research for Nursing*, 20(4),

393–402.

Nakamura, H., Yoshimura, K., McElvaney, N. G., & Crystal, R. G. (1992). Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. *Journal of Clinical Investigation*, 89, 1478-1484.

Papageorgiou, M., Stiakaki, E., Dimitriou, H., Malliaraki, N., Notas, G., Castanas, E., & Kalmanti, M. (2005). Cancer chemotherapy reduces plasma total antioxidant capacity in children with malignancies. *Leukemia Research*, 29(1), 11-16.

Pellegrini-Giampietro, D. E., Cherici, G., Alesiani, M., Carla, V., & Moroni, F. (1990). Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. *Journal of Neuroscience*, 10, 1035-1041.

Petrou, P., Demerouti, E., & Schaufeli, W. B. (2018). Crafting the change: The role of employee job crafting behaviors for successful organizational change. *Journal of Management*, 44, 1766-1792.

Pratico, D., MY Lee, V., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998). Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. *FASEB Journal*, 12, 1777-1783.

Pyne-Geithman, G. J., Morgan, C. J., Wagner, K., Dulaney, E. M., Carrozzella, J., Kanter, D. S., ... Clark, J. F. (2005). Bilirubin production and oxidation in CSF of patients with cerebral vasospasm after subarachnoid hemorrhage. *Journal of Cerebral Blood Flow and Metabolism*, 25, 1070-1077.

- 1
2
3 Qiao, Y. C., Shen, J., He, L., Hong, X. Z., Tian, F., Pan, Y. H., ... Zhao, H. L. (2016). Changes
4 of regulatory t cells and of proinflammatory and immunosuppressive cytokines in
5 patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Journal of*
6 *Diabetes Research*, 2016, 3694957.
- 7
8
9
10
11 Revill, S. I., Robinson, J. O., Rosen, M., & Hogg, M. I. (1976). The reliability of a linear analogue
12 for evaluating pain. *Anaesthesia*, 31, 1191-1198.
- 13
14
15
16 Rodgers, C., Sanborn, C., Taylor, O., Gundy, P., Pasvogel, A., (Ki), I. M., & Hockenberry, M. J.
17 (2016). Fatigue and oxidative stress in children undergoing leukemia treatment.
18 *Biological Research for Nursing*, 18(5), 515–520.
- 19
20
21
22 SAS Institute Inc. (2011). *SAS/STAT® 9.3 User's Guide*. Cary, NC: SAS Institute Inc.
- 23
24 Scott, J., & Huskisson, E. C. (1979). Vertical or horizontal visual analogue scales. *Annals of the*
25 *Rheumatic Diseases*, 38, 560.
- 26
27
28 Shohami, E., Beit-Yannai, E., Horowitz, M., & Kohen, R. (1997). Oxidative stress in closed-head
29 injury: brain antioxidant capacity as an indicator of functional outcome. *Journal of*
30 *Cerebral Blood Flow and Metabolism*, 17, 1007-1019.
- 31
32
33
34
35 Sousa, K. H., Kwok, O. M., Schmiede, S. J., & West, S. G. (2014). A longitudinal approach to
36 understanding the relationship between symptom status and QOL. *Western Journal of*
37 *Nursing Research*, 36, 732-747.
- 38
39
40
41 Stenzel, S. L., Krull, K. R., Hockenberry, M., Jain, N., Kaemingk, K., Moore, I. M. (2010).
42 *Oxidative stress and neurobehavioral problems in pediatric ALL patients undergoing*
43 *chemotherapy. Journal of Pediatric Hematology Oncology*, 32(2), 113-118.
- 44
45
46
47
48 Sznurkowska, K., Bockowska, M., Zielinski, M., Plata-Nazar, K., Trzonkowski, P., Liberek, A., ...
49 Szlagatys-Sidorkiewicz, A. (2018). Peripheral regulatory T cells and anti-inflammatory
50 cytokines in children with juvenile idiopathic arthritis. *Acta Biochimica Polonica*, 65, 119-
51 123.
- 52
53
54
55
56
57
58
59
60

- 1
2
3 Tasian, S. K., Loh, M. L., & Hunger, S. P. (2015). Childhood acute lymphoblastic leukemia:
4
5 Integrating genomics into therapy. *Cancer*, *121*, 3577-3590.
6
7 Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014). Cytokines and chemokines: At
8
9 the crossroads of cell signalling and inflammatory disease. *Biochimica et Biophysica*
10
11 *Acta*, *1843*, 2563-2582.
12
13 Weber, G. (1994). The pathophysiology of reactive oxygen intermediates in the central nervous
14
15 system. *Medical Hypotheses*, *43*, 223-230.
16
17 Winkler, M. R., Park, J., Pan, W., Brandon, D. H., Scher, M., & Holditch-Davis, D. (2017). Does
18
19 preterm period sleep development predict early childhood growth trajectories? *Journal of*
20
21 *Perinatology*, *37*, 1047-1052.
22
23 Wong, D. L., & Baker, C. M. (1988). Pain in children: comparison of assessment scales.
24
25 *Pediatric Nursing*, *14*, 9-17.
26
27
28 Yeh, C. H., Chiang, Y. C., Chien, L. C., Lin, L., Yang, C. P., & Chuang, H. L. (2008). Symptom
29
30 clustering in older Taiwanese children with cancer. *Oncology Nursing Forum*, *35*, 273-
31
32 281.
33
34
35 Yiotaldiotariotam, M., Singh, A. S., te Velde, S. J., van Stralen, M. M., MacKinnon, D. P., Brug,
36
37 J., ... Chinapaw, M. J. (2013). Mediators of longitudinal changes in measures of
38
39 adiposity in teenagers using parallel process latent growth modeling. *Obesity*, *21*, 2387-
40
41 2395.
42
43 Zimmermann, H. W., Seidler, S., Gassler, N., Nattermann, J., Luedde, T., Trautwein, C., &
44
45 Tacke, F. (2011). Interleukin-8 is activated in patients with chronic liver diseases and
46
47 associated with hepatic macrophage accumulation in human liver fibrosis. *PLoS One*, *6*,
48
49 e21381.
50
51
52
53
54
55
56
57
58
59
60

Figure Captions

Figure 1. Biochemical mechanisms and symptoms during childhood cancer treatment.

Figure 2. The final parsimonious model of the longitudinal relationships between biomarkers and symptom cluster in terms of their growth parameters (intercepts and slopes) with standardized estimates. ($\dagger p < .10$. $*p < .05$. $**p < .01$. $***p < .001$).

For Peer Review

Table 1. Factor Loadings and Variance Explained in One-Factor Solution for Symptom Cluster at Each Time Point

<u>Symptom</u>	<u>Factor—Symptom Cluster</u>			
	<u>Time 1</u>	<u>Time 2</u>	<u>Time 3</u>	<u>Time 4</u>
<u>Fatigue</u>	<u>.76</u>	<u>.71</u>	<u>.73</u>	<u>.88</u>
<u>Pain</u>	<u>.73</u>	<u>.64</u>	<u>.72</u>	<u>.49</u>
<u>Nausea</u>	<u>.53</u>	<u>.59</u>	<u>.56</u>	<u>.35</u>
<u>Variance Explained</u>	<u>63.2%</u>	<u>61.3%</u>	<u>63.2%</u>	<u>54.0%</u>

Table 1. Symptom Measures

Symptom	Score Used in Data Analysis	Severity Classification		
		Mild	Moderate	Severe
Instruments	(Scale Range)			
Fatigue	T-score of total			
–Child Fatigue Scale (CFS) ^a	score (20-80)	≤ 28	29-37	≥ 38
–Adolescent Fatigue Scale (FSA) ^b		≤ 35	36-55	≥ 56
–Parent Fatigue Scale (PFS) ^c		≤ 39	40-56	≥ 56
Pain	Raw score (1-6)	≤ 2	3-4	≥ 5
–Wong-Baker Faces Scale ^d				
Nausea	Raw score (0-100)	≤ 20	30-40	≥ 50
–Visual Analog Scale (VAS) ^e				

^aHinds et al. (2010).

^bMandrell et al. (2011).

^cHockenberry et al. (2003).

^dWong and Baker (1988).

^eScott and Huskisson (1979) and Revill et al. (1976).

Table 2. Sample Characteristics and Baseline Biomarker Information (*N* = 218)

Characteristic		Mean /	SD /
		Frequency (<i>n</i>)	Percent (%)
Age (years)		8.38	4.48
Sex	<i>Female</i>	96	44.0
	<i>Male</i>	122	56.0
Race/ Ethnicity	<i>Hispanic</i>	95	43.6
	<i>Non-Hispanic White</i>	87	39.9
	<i>Non-Hispanic Black</i>	18	8.3
	<i>Non-Hispanic Other</i>	18	8.3
Leukemia Risk Category	<i>Very High</i>	71	32.6
	<i>High</i>	47	21.6
	<i>Average/Standard</i>	76	34.9
	<i>Low</i>	24	11.0
Biomarkers at Baseline (pg/ml)	<i>F2-Isoprostanes</i>	8.38	10.42
	<i>IL-8</i>	142.77	112.20

Table 3. Means (*M*s) and Standard Deviations (*SD*s) of the Longitudinal Variables by Time (*N* = 218)

Variable (Scale Range)	Time 1			Time 2			Time 3			Time 4		
	<i>n</i>	<i>M</i>	<i>SD</i>	<i>n</i>	<i>M</i>	<i>SD</i>	<i>n</i>	<i>M</i>	<i>SD</i>	<i>n</i>	<i>M</i>	<i>SD</i>
<i>Symptom Measures</i>												
Fatigue (20-80) ^a	195	53.92	9.98	210	49.97	10.36	196	48.20	9.10	193	46.70	8.09
Pain (1-6) ^b	193	2.57	2.22	207	1.66	2.15	194	1.32	1.60	191	1.29	1.80
Nausea (0-100) ^c	192	14.33	21.53	206	14.06	21.43	192	15.52	21.35	192	12.05	19.14
<i>Biomarkers (pg/ml)</i>												
F2-Isoprostanes	195	7.49	8.77	209	6.36	5.17	196	6.58	7.71	194	6.66	8.42
IL-8	193	113.54	103.85	206	84.85	74.74	196	73.15	53.75	193	87.22	90.37


^aMeasured using the Child Fatigue Scale (CFS; Hinds et al., 2010), the Adolescent Fatigue Scale (FSA; Mandrell et al., 2011), and the Parent Fatigue Scale (PFS; Hockenberry et al., 2003). All the scores from the three instruments were converted to comparable, standardized T-scores.

^bMeasured using the Wong-Baker Faces Scale (Wong & Baker, 1988).


^cMeasured using the Visual Analog Scale (VAS; Scott & Huskisson, 1979; Revill et al., 1976).

Table 4. Factor Loadings and Variance Explained in One-Factor Solution for Symptom Cluster at Each Time Point

Symptom	Factor—Symptom Cluster			
	Time 1	Time 2	Time 3	Time 4
Fatigue	.76	.71	.73	.88
Pain	.73	.64	.72	.49
Nausea	.53	.59	.56	.35
Variance Explained	63.2%	61.3%	63.2%	54.0%



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41